PDR001A
Biological
Novartis Pharmaceuticals Corporation
Total Payments
$1.1M
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1.1M | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ADJUV THERAPY IN DRB, TMT AND PDR | Novartis Pharmaceuticals Corporation | $715,412 | 0 |
| CPDR001A0US03CT: PHASE II STUDY OF PDR001 IN COMBINATION WITH MAPK PATHWAY INHIBITORS IN PATIENTS WITH RAI-REFRACTORY THYROID CANCER | Novartis Pharmaceuticals Corporation | $411,119 | 0 |
Top Doctors Receiving Payments for PDR001A
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $1.1M | 2 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $1.1M
- Total Doctors 0
- Transactions 2
About PDR001A
PDR001A is a biological associated with $1.1M in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $1.1M was paid across 2 transactions to 0 doctors.
The most common payment nature for PDR001A is "Unspecified" ($1.1M, 100.0% of total).
PDR001A is associated with 2 research studies, including "ADJUV THERAPY IN DRB, TMT AND PDR" ($715,412).